Top

Published in:

01-04-2017 | ORIGINAL ARTICLE

Intracerebroventricular Streptozotocin as a Model of Alzheimer’s Disease: Neurochemical and Behavioral Characterization in Mice

Authors: Katherine Garcia Ravelli, Barbara dos Anjos Rosário, Rosana Camarini, Marina Sorrentino Hernandes, Luiz Roberto Britto

Published in: Neurotoxicity Research | Issue 3/2017

Abstract

Streptozotocin has been widely used to mimic some aspects of Alzheimer’s disease (AD). However, especially in mice, several characteristics involved in the streptozotocin (STZ)-induced AD pathology are not well known. The main purpose of this study was to evaluate temporally the expression of AD-related proteins, such as amyloid-β (Aβ), choline acetyltransferase (ChAT), synapsin, axonal neurofilaments, and phosphorylated Tau in the hippocampus following intracerebroventricular (icv) administration of STZ in adult mice. We also analyzed the impact of STZ on short- and long-term memory by novel object recognition test. Male mice were injected with STZ or citrate buffer, and AD-related proteins were evaluated by immunoblotting assays in the hippocampus at 7, 14, or 21 days after injection. No differences between the groups were found at 7 days. The majority of AD markers evaluated were found altered at 14 days, i.e., the STZ group showed increased amyloid-β protein and neurofilament expression, increased phosphorylation of Tau protein, and decreased synapsin expression levels compared to controls. Except for synapsin, all of these neurochemical changes were transient and did not last up to 21 days of STZ injection. Moreover, both short-term and long-term memory deficits were demonstrated after STZ treatment at 14 and 21 days after STZ treatment.

Blokland A, Jolles J (1993) Spatial learning deficit and reduced hippocampal ChAT activity in rats after an ICV injection of streptozotocin. Pharmacol Biochem Behav 44:491–494CrossRefPubMed

Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol Scand Suppl 165:3–12CrossRefPubMed

Chen Y et al (2013) A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 47:711–725. doi:10.1007/s12035-012-8375-5 CrossRefPubMed

Chen Y et al (2014) Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice1. Mol Neurobiol 49:547–562. doi:10.1007/s12035-013-8539-y CrossRefPubMed

Chung SH (2009) Aberrant phosphorylation in the pathogenesis of Alzheimer’s disease. BMB Rep 42:467–474CrossRefPubMed

DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 27:457–464. doi:10.1002/ana.410270502 CrossRefPubMed

Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer’s disease. In: Am J Pathol, vol 175. vol 5. United States, pp 2089–2098. doi:10.2353/ajpath.2009.090157

Elcioglu HK, Aslan E, Ahmad S, Alan S, Salva E, Elcioglu OH, Kabasakal L (2016) Tocilizumab’s effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer’s model. Mol Cell Biochem 420:21–28. doi:10.1007/s11010-016-2762-6 CrossRefPubMed

Goedert M (1996) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Ann N Y Acad Sci 777:121–131CrossRefPubMed

Grunblatt E, Hoyer S, Riederer P (2004) Gene expression profile in streptozotocin rat model for sporadic Alzheimer’s disease. J Neural Transm 111:367–386. doi:10.1007/s00702-003-0030-x CrossRefPubMed

Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101:757–770. doi:10.1111/j.1471-4159.2006.04368.x CrossRefPubMed

Hu YY et al (2002) Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 320:156–160CrossRefPubMed

Kar S, Slowikowski SP, Westaway D, Mount HT (2004) Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J Psychiatry Neurosci 29:427–441PubMedPubMedCentral

Knezovic A, Osmanovic-Barilar J, Curlin M, Hof PR, Simic G, Riederer P, Salkovic-Petrisic M (2015) Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer’s disease. J Neural Transm (Vienna) 122:577–592. doi:10.1007/s00702-015-1394-4 CrossRef

Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112:1199–1208CrossRefPubMed

Lannert H, Wirtz P, Schuhmann V, Galmbacher R (1998) Effects of estradiol (−17beta) on learning, memory and cerebral energy metabolism in male rats after intracerebroventricular administration of streptozotocin. J Neural Transm 105:1045–1063CrossRefPubMed

Lee MK, Cleveland DW (1996) Neuronal intermediate filaments. Annu Rev Neurosci 19:187–217. doi:10.1146/annurev.ne.19.030196.001155 CrossRefPubMed

Li M, Chen L, Lee DH, Yu LC, Zhang Y (2007) The role of intracellular amyloid beta in Alzheimer’s disease. In: Prog Neurobiol, vol 83. vol 3. England, pp 131–139. doi:10.1016/j.pneurobio.2007.08.002

Liu P, Zou LB, Wang LH, Jiao Q, Chi TY, Ji XF, Jin G (2014) Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats. Psychopharmacology 231:345–356. doi:10.1007/s00213-013-3240-4 CrossRefPubMed

Liu Q, Xie F, Alvarado-Diaz A, Smith MA, Moreira PI, Zhu X, Perry G (2011) Neurofilamentopathy in neurodegenerative diseases. Open Neurol J 5:58–62. doi:10.2174/1874205X01105010058 CrossRefPubMedPubMedCentral

Majkutewicz I et al (2016) Dimethyl fumarate attenuates intracerebroventricular streptozotocin-induced spatial memory impairment and hippocampal neurodegeneration in rats. Behav Brain Res 308:24–37. doi:10.1016/j.bbr.2016.04.012 CrossRefPubMed

Muller AP et al (2012) Physical exercise exacerbates memory deficits induced by intracerebroventricular STZ but improves insulin regulation of H(2)O(2) production in mice synaptosomes. J Alzheimers Dis 30:889–898. doi:10.3233/jad-2012-112066 PubMed

Muller D, Nitsch RM, Wurtman RJ, Hoyer S (1998) Streptozotocin increases free fatty acids and decreases phospholipids in rat brain. J Neural Transm 105:1271–1281CrossRefPubMed

Muller-Spahn F, Hock C (1999) Risk factors and differential diagnosis of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 249(Suppl 3):37–42CrossRefPubMed

Nakamura Y et al (1997) Abnormal distribution of neurofilament L in neurons with Alzheimer’s disease. Neurosci Lett 225:201–204CrossRefPubMed

Perdahl E, Adolfsson R, Alafuzoff I, Albert KA, Nestler EJ, Greengard P, Winblad B (1984) Synapsin I (protein I) in different brain regions in senile dementia of Alzheimer type and in multi-infarct. Dementia. J Neural Transm 60:133–141CrossRefPubMed

Pinton S, da Rocha JT, Zeni G, Nogueira CW (2010) Organoselenium improves memory decline in mice: involvement of acetylcholinesterase activity. In: Neurosci Lett, vol 472. vol 1. 2010 Elsevier Ireland Ltd, Ireland, pp 56–60. doi:10.1016/j.neulet.2010.01.057

Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer’s disease and transgenic models. Annu Rev Neurosci 21:479–505. doi:10.1146/annurev.neuro.21.1.479 CrossRefPubMed

Reitz C, Honig L, Vonsattel JP, Tang MX, Mayeux R (2009) Memory performance is related to amyloid and tau pathology in the hippocampus. J Neurol Neurosurg Psychiatry 80:715–721. doi:10.1136/jnnp.2008.154146 CrossRefPubMedPubMedCentral

Santos DB et al (2015) Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice. Neuroscience 284:590–600. doi:10.1016/j.neuroscience.2014.10.019 CrossRefPubMed

Santos TO, Mazucanti CH, Xavier GF, Torrao AS (2012) Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. Physiol Behav 107:401–413. doi:10.1016/j.physbeh.2012.06.019 CrossRefPubMed

Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766PubMed

Sharma B, Singh N, Singh M, Jaggi AS (2008) Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia. In: Pharmacol Biochem Behav, vol 89. vol 4. United States, pp 535–545. doi:10.1016/j.pbb.2008.02.012

Shoham S, Bejar C, Kovalev E, Schorer-Apelbaum D, Weinstock M (2007) Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 52:836–843. doi:10.1016/j.neuropharm.2006.10.005 CrossRefPubMed

Spires TL, Hyman BT (2005) Transgenic models of Alzheimer’s disease: learning from animals. NeuroRx 2:423–437. doi:10.1602/neurorx.2.3.423 CrossRefPubMedPubMedCentral

Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:537–546PubMed

Tota S, Awasthi H, Kamat PK, Nath C, Hanif K (2010) Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res 209:73–79. doi:10.1016/j.bbr.2010.01.017 CrossRefPubMed

Wang H, Cheng H, Che Z (2016) Ameliorating effect of luteolin on memory impairment in an Alzheimer’s disease model. Mol Med Rep 13:4215–4220. doi:10.3892/mmr.2016.5052 PubMedPubMedCentral

Wang J, Tung YC, Wang Y, Li XT, Iqbal K, Grundke-Iqbal I (2001) Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett 507:81–87CrossRefPubMed

Title: Intracerebroventricular Streptozotocin as a Model of Alzheimer’s Disease: Neurochemical and Behavioral Characterization in Mice
Authors: Katherine Garcia Ravelli
Barbara dos Anjos Rosário
Rosana Camarini
Marina Sorrentino Hernandes
Luiz Roberto Britto
Publication date: 01-04-2017
Publisher: Springer US
Published in: Neurotoxicity Research / Issue 3/2017
Print ISSN: 1029-8428
Electronic ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-016-9684-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intracerebroventricular Streptozotocin as a Model of Alzheimer’s Disease: Neurochemical and Behavioral Characterization in Mice

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Neutrophil-To-Lymphocyte Ratio Predicts 3-Month Outcome of Acute Ischemic Stroke

Human Umbilical Cord Blood-Derived Neural Stem Cell Line as a Screening Model for Toxicity

Aminoglycoside Increases Permeability of Osseous Spiral Laminae of Cochlea by Interrupting MMP-2 and MMP-9 Balance

The Impact of CB2 Receptor Ligands on the MK-801-Induced Hyperactivity in Mice

Nitric Oxide Production in the Striatum and Cerebellum of a Rat Model of Preterm Global Perinatal Asphyxia

Neuroprotective Efficacy of Mitochondrial Antioxidant MitoQ in Suppressing Peroxynitrite-Mediated Mitochondrial Dysfunction Inflicted by Lead Toxicity in the Rat Brain